Candidiasis Therapeutics Market - 2024-2031

January 2024 | 50 pages | ID: C0199C73D659EN
DataM Intelligence

Abstracts

Candidiasis Therapeutics Marketis is growing with a CAGR of 5.30% during the forecast period 2026-2035.

The Candidiasis Therapeutics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Candidiasis Therapeutics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Type

• Oral Candidiasis*
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis

By Drug Class

• Polyene*
• Nystatin (Mycostatin and others)
• Amphotericin B (Fungizone, Amphocin)
• Azole Antifungals
• Fluconazole (Diflucan)
• Itraconazole (Sporanox)
• Voriconazole (Vfend)
• Posaconazole (Noxafil)
• Topical azoles
• Clotrimazole (Mycelex, Femizole-7)
• Butoconazole (Femstat-3, Gynazole-1)
• Miconazole vaginal (Monistat, Micatin)
• Tioconazole (Vagistat-1)
• Terconazole vaginal (Terazol-7, Terazol-3)
• Glucan synthesis inhibitors (echinocandins)
• Caspofungin (Cancidas)
• Micafungin (Mycamine)
• Anidulafungin (Eraxis)
• Antimetabolite
• Flucytosine (Ancobon)
• Allylamines
• Terbinafine (Daskil, Lamisil)
• Others

By Route of Administration

• Oral*
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies*
• Online Pharmacies
• Retail Pharmacies
• Others

Regional Analysis for Candidiasis Therapeutics Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Candidiasis Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. GLOBAL CANDIDIASIS THERAPEUTICS MARKET METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DEFINITION AND OVERVIEW

3. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - EXECUTIVE SUMMARY

3.1. Market Snippet by Type
3.2. Market Snippet by Drug Class
3.3. Market Snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region

4. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing number of patients affected by candidiasis infection
    4.1.1.2. Growing awareness of candidiasis infection
    4.1.1.3. XX
  4.1.2. Restraints:
    4.1.2.1. Availability of alternative treatments
    4.1.2.2. Side-effects caused by the drugs
    4.1.2.3. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - INDUSTRY ANALYSIS

5.1. Epidemiology
5.2. Pipeline Analysis
5.3. Porter's Five Forces Analysis
5.4. Supply Chain Analysis
5.5. Clinical Trials
5.6. Pricing Analysis
5.7. Regulatory Analysis
5.8. Reimbursement Analysis
5.9. Unmet Needs

6. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  7.1.2. Market Attractiveness Index, By Type Segment
7.2. Oral Candidiasis*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Vulvovaginal Candidiasis
7.4. Cutaneous Candidiasis
7.5. Invasive Candidiasis
7.6. Systemic Candidiasis

8. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DRUG CLASS

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  8.1.2. Market Attractiveness Index, By Drug Class Segment
8.2. Polyene*
  8.2.1. Introduction
  8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  8.2.3. Nystatin (Mycostatin and others)
  8.2.4. Amphotericin B (Fungizone, Amphocin)
8.3. Azole Antifungals
  8.3.1. Fluconazole (Diflucan)
  8.3.2. Itraconazole (Sporanox)
  8.3.3. Voriconazole (Vfend)
  8.3.4. Posaconazole (Noxafil)
8.4. Topical azoles
  8.4.1. Clotrimazole (Mycelex, Femizole-7)
  8.4.2. Butoconazole (Femstat-3, Gynazole-1)
  8.4.3. Miconazole vaginal (Monistat, Micatin)
  8.4.4. Tioconazole (Vagistat-1)
  8.4.5. Terconazole vaginal (Terazol-7, Terazol-3)
8.5. Glucan synthesis inhibitors (echinocandins)
  8.5.1. Caspofungin (Cancidas)
  8.5.2. Micafungin (Mycamine)
  8.5.3. Anidulafungin (Eraxis)
8.6. Antimetabolite
  8.6.1. Flucytosine (Ancobon)
8.7. Allylamines
  8.7.1. Terbinafine (Daskil, Lamisil)
8.8. Others

9. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY ROUTE OF ADMINISTRATION

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  9.1.2. Market Attractiveness Index, By Route of Administration Segment
9.2. Oral*
  9.2.1. Introduction
  9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Parenteral
9.4. Topical

10. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DISTRIBUTION CHANNEL

10.1. Introduction
  10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacies*
  10.2.1. Introduction
  10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Others

11. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. The U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. The U.K.
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of key companies to watch
12.5. List of the company with disruptive technology
12.6. List of start-up companies

13. GLOBAL CANDIDIASIS THERAPEUTICS MARKET- COMPANY PROFILES

13.1. Cidara Therapeutics Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. NovaDigm Therapeutics Inc
13.3. Amplyx Pharmaceuticals Inc.
13.4. Astellas Pharma Inc.
13.5. Basilea Pharmaceutica Ltd.
13.6. Grupo Ferrer Internacional, S.A.
13.7. Pacgen Biopharmaceuticals
13.8. Viamet Pharmaceuticals Holdings, LLC
13.9. Mycovia Pharmaceuticals Inc
13.10. Novabiotics Limited
13.11. Bayer AG
13.12. Biomar Microbial Technologies
13.13. Merck
13.14. Scynexis Inc.
13.15. Pfizer, Inc. (*LIST NOT EXHAUSTIVE)

14. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - DATAM

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us